Blueprint Medicines (BPMC)- The current $ 3.75 billion valuation compares favorably to $ 2 billion peak
sales potential of two lead drug candidates, while their
solid cash position after the December secondary offering and their deep
pipeline provide adequate cushion to the current share price.
Thought a pipe dream for almost two decades, the Turkmenistan - Afghanistan - Pakistan - India (TAPI)
pipeline took
solid shape in May 2012, with the signing of gas
sale and pricing agreements.